RxDoctor Payments DataLook up a doctor →

Laura Mulka, APRN

Adult Health · Wethersfield, CTNPI 1861493611

Payments from drug & device makers

$305,819in general payments, 2019–2025

Across 1,055 payments — averaging $289.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$55K
  • Sanofi$52K
  • Johnson & Johnson$40K
  • Sobi, Inc$37K
  • E.r. Squibb & Sons, L.L.C.$34K
  • Beigene USA, Inc.$26K
  • plus $61K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)112$55,061
Sanofi115$52,130
Johnson & Johnson(2 entities)84$39,957
Sobi, Inc81$36,992
E.r. Squibb & Sons, L.L.C.97$34,066
Beigene USA, Inc.44$26,205
Beone Medicines USA, Inc.31$17,976
Genentech USA, Inc.20$9,385
Epizyme, Inc.27$8,825
Incyte Corporation39$8,053
Bristol Myers Squibb24$6,271
Cumberland Pharmaceuticals, Inc.2$1,739
Ipsen Biopharmaceuticals, Inc14$1,249
Myriad Genetic Laboratories, Inc.24$1,019
Pfizer42$664
Merck33$653
Rigel Pharmaceuticals, Inc.22$421
Lilly USA, LLC22$382
Novartis18$376
Takeda Pharmaceuticals U.S.A., Inc.16$353
AbbVie15$347
Jazz Pharmaceuticals Inc.18$320
Amgen11$315
Astellas Pharma US Inc12$301
Bayer14$263
GSK11$219
Array Biopharma Inc13$210
Gilead(2 entities)9$193
Geron Corporation7$161
Daiichi Sankyo Inc.7$135
Eisai Inc.7$123
AVEO Pharmaceuticals, Inc.2$116
Regeneron Healthcare Solutions, Inc.6$106
Sanofi-aventis U.S. LLC1$100
Pharmaessentia USA Corporation4$100
Mirati Therapeutics, Inc.4$91
Servier Pharmaceuticals LLC4$88
Seagen Inc.5$82
Coherus Oncology, Inc.3$64
Stemline Therapeutics Inc.3$59
ADC Therapeutics America, Inc.3$52
Taiho Oncology, Inc.2$45
Sumitomo Pharma America, Inc.2$44
Exelixis Inc.2$40
Puma Biotechnology, Inc.2$39
Springworks Therapeutics, Inc.2$38
Organon2$38
Novocure Inc.1$35
Boehringer Ingelheim1$33
Blueprint Medicines Corporation1$30
Novo Nordisk1$24
Adaptive Biotechnologies Corporation1$23
Telix Pharmaceuticals1$22
GE HealthCare1$21
Genmab U.S., Inc.1$21
Fennec Pharmaceuticals, Inc.1$21
Relievant Medsystems, Inc.1$21
EMD Serono, Inc.1$19
Octapharma USA, Inc.1$18
Deciphera Pharmaceuticals Inc.1$18

How this compares

$305,819 in reported general payments places this provider in the 95th percentile of 418 adult health providers in Connecticut.

See all adult health providers in Connecticut →

Medicare billing

Part B allowed, 2024
$1,152,930
Medicare patients
224
Services billed
57,198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other adult health in Wethersfield

See the full list for Connecticut →

Where these figures come from

Is this you, or does something look wrong? →